UROGEN PHARMA
PharmaUROGEN PHARMA is a pharmaceutical company focused on Oncology. Key products include JELMYTO.
UROGEN PHARMA at a Glance
- Fast trial execution (25 months median completion)
UROGEN PHARMA's Key Drugs
UROGEN PHARMA's core commercial portfolio centers on JELMYTO, ZUSDURI, spanning Oncology — its most strategically important drugs approved in the last 15 years.
UROGEN PHARMA's Recent FDA Approvals
UROGEN PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
UROGEN PHARMA's Therapeutic Areas
UROGEN PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UROGEN PHARMA's Top Competitors
UROGEN PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UROGEN PHARMA Pipeline Snapshot
UROGEN PHARMA has 10 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 2 Phase 2 and 1 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • JELMYTO leads revenue
- • 2 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/7 completed
- • Speed: 25 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges